Drug Regulation in India, Organizations, Legal Framework, Challenges

Drug Regulation in India is a critical public health function that ensures medicines are safe, effective and of high quality before reaching patients. India is known as the “Pharmacy of the World,” supplying nearly 20% of global generic medicines and over 60% of vaccines exporting to about 200 countries. This vast scale makes regulation highly important. 

Drug Regulation in India

The Drug Regulation in India involves multiple laws, institutions and processes working together to monitor manufacturing, clinical trials, pricing and post market safety of drugs. However, repeated incidents of substandard drugs since 2020 highlight gaps in enforcement, coordination and transparency that affect both domestic health and global credibility.

Drug Regulation in India Organizations

Drug Regulation in India structure includes central, state and specialized bodies working together to regulate manufacturing, approval, pricing and safety monitoring of pharmaceuticals nationwide.

• Central Drugs Standard Control Organization (CDSCO): CDSCO functions under the Ministry of Health and Family Welfare and is headed by the Drugs Controller General of India (DCGI). It approves new drugs, regulates clinical trials, sets standards and controls imports and exports of medicines.
• Central Drugs Laboratory (CDL): Located in Kolkata, CDL acts as the national reference laboratory for drug testing. It resolves disputes related to drug quality, conducts testing, develops standards and trains analysts including WHO fellows.
• State Drug Control Departments: These authorities operate under state governments and are responsible for licensing manufacturing units, inspecting facilities, monitoring local markets and taking legal action against adulterated or spurious drugs.
• State Drug Testing Laboratories: These laboratories analyze drug samples collected by inspectors and provide scientific evidence for regulatory action. However, many labs face shortages of modern equipment and skilled personnel, reducing effectiveness.
• Pharmacovigilance Programme of India (PvPI): PvPI monitors adverse drug reactions through a network of reporting centers. It collects safety data and recommends regulatory action, but India contributes only about 3% to the global safety database.
• National Pharmaceutical Pricing Authority (NPPA): NPPA regulates drug prices through the Drugs (Prices Control) Order. It ensures affordability by fixing ceiling prices for essential medicines and monitoring market pricing practices.
• Drugs Technical Advisory Board (DTAB): DTAB advises the central government on technical matters related to drug regulation, including standards, testing protocols and amendments to regulatory frameworks.
• Drugs Consultative Committee (DCC): DCC ensures coordination between central and state regulators to maintain uniform implementation of drug laws across India’s federal system.
• Directorate General of Health Services (DGHS): DGHS provides technical guidance on public health and supports drug regulation through policy recommendations and coordination with regulatory bodies.
• Indian Council of Medical Research (ICMR): ICMR supports clinical research, drug trials and scientific validation, contributing to evidence based drug regulation and policy decisions in India.

‹ ›

Drug Regulation in India Legal Frameworks

Drug Regulation in India is governed by multiple laws, rules and schemes that define standards, licensing, safety monitoring and pricing mechanisms across the pharmaceutical sector.

• Drugs and Cosmetics Act 1940: This is the primary legislation regulating drug import, manufacture, sale and distribution. It ensures safety, efficacy and quality while providing penalties for adulteration and substandard drugs.
• Drugs and Cosmetics Rules, 1945: These rules provide operational details such as licensing procedures, classification of drugs, labeling requirements and Good Manufacturing Practices under Schedule M for quality assurance.
• Pharmacy Act 1948: This Act regulates the profession of pharmacy by setting standards for education and registration of pharmacists, ensuring qualified personnel handle drug dispensing.
• Drugs and Magic Remedies (Objectionable Advertisements) Act 1954: It prohibits misleading advertisements claiming magical cures, protecting consumers from false claims related to drugs and treatments.
• Narcotic Drugs and Psychotropic Substances Act 1985: This law regulates narcotic and psychotropic substances, ensuring controlled medical use while preventing misuse and illegal trafficking.
• Drugs (Prices Control) Order (DPCO), 2013: Implemented by NPPA, it controls the prices of essential medicines to ensure affordability and prevent excessive pricing by pharmaceutical companies.
• New Drugs and Clinical Trials Rules, 2019: These rules streamline clinical trial approvals, ensure ethical standards and provide compensation mechanisms for trial related injuries or deaths.
• Strengthening of States’ Drug Regulatory System (SSDRS): A centrally sponsored scheme aimed at improving infrastructure, laboratories and manpower at the state level for better enforcement.
• Schedule M (WHO GMP Standards): This provision integrates global Good Manufacturing Practices into Indian regulations, ensuring quality manufacturing processes in pharmaceutical units.
• Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS): This scheme supports small and medium pharmaceutical companies with turnover below ₹500 crore to upgrade technology and improve drug quality standards.

Drug Regulation in India Challenges

The system of Drug Regulation in India faces multiple structural, technical and governance related challenges that affect drug safety, quality control and global trust in Indian pharmaceuticals.

• Repeated Drug Safety Incidents: Since 2020, multiple tragedies including deaths in Jammu, Gambia, Uzbekistan, Cameroon and Delhi due to contaminated drugs.
• Quality Control Failures: Conflicting test results between state laboratories and CDL create uncertainty in drug quality assessment, weakening enforcement and raising concerns about reliability of testing processes.
• Outdated Testing Systems: Use of wax seals, manual documentation and postal communication creates risks of sample tampering, delays and inefficiencies compared to modern digital tracking systems.
• Fragmented Regulatory Structure: Division of responsibilities between central and state authorities leads to overlapping jurisdictions, weak coordination and inconsistent enforcement across different regions.
• Pharmacovigilance Gaps: Underreporting of adverse drug reactions remains a major issue, with limited awareness among healthcare professionals and patients about reporting mechanisms.
• Global Reputation Risks: WHO estimates that one in ten medicines in developing countries may be substandard and repeated export related incidents have raised questions about India’s reliability as a global supplier.

Way Forward

• Strengthening State Infrastructure: Increasing the number of inspectors, upgrading laboratories and providing advanced training will improve enforcement capacity at the state level and ensure better compliance monitoring.
• Improved Centre-State Coordination: Strengthening the role of DCC and promoting joint inspections between CDSCO and states will ensure uniform enforcement and reduce regulatory fragmentation across regions.
• Expanding Pharmacovigilance: Increasing awareness, improving reporting systems and integrating digital tools will enhance detection of adverse drug reactions and shift from reactive to proactive safety monitoring.
• Legal Framework Modernization: Updating the Drugs and Cosmetics Act 1940 to address modern challenges such as biologics, online pharmacies and data integrity will strengthen regulatory effectiveness.
• Promoting Research and Innovation: Establishing Centers of Excellence in Drug Regulatory Science and encouraging collaboration with academic institutions will support evidence based policymaking and technological advancement.